Security
Natera, Inc. Common Stock · NTRA
NTRANASDAQCommon stockCurrentCIK 1604821Updated Oct 4, 2026
Name history
Natera, Inc. · through Oct 1, 2026
NTRA price & chart
Loading TradingView…
NASDAQ:NTRA on TradingView ↗About the company
Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,398,344,000Source | 1,660,735,000Source | 1,441,699,000Source | 1,394,474,000Source |
| Property, Plant and Equipment, NetUSD | 241,184,000Source | 162,046,000Source | 111,210,000Source | 92,453,000Source |
| GoodwillUSD | 141,070,000Source | — | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 373,713,000Source | — | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | — | — | 466,005,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 296,528,000Source | 314,165,000Source | 278,289,000Source | 244,385,000Source |
| Inventory, NetUSD | 68,443,000Source | 44,744,000Source | 40,759,000Source | 35,406,000Source |
| Assets, CurrentUSD | 1,496,939,000Source | 1,375,820,000Source | 1,258,549,000Source | 1,211,817,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 55,828,000Source | 48,635,000Source | 60,524,000Source | 33,634,000Source |
| Operating Lease, Right-of-Use AssetUSD | 108,541,000Source | 86,149,000Source | 56,537,000Source | 71,874,000Source |
| Other Assets, NoncurrentUSD | 36,897,000Source | 36,720,000Source | 15,403,000Source | 18,330,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 685,931,000Source | 465,315,000Source | 676,372,000Source | 688,730,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 14,000Source | 12,000Source | 11,000Source | 11,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,776,022,000Source | -2,567,862,000Source | -2,377,436,000Source | -1,942,635,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -258,000Source | -344,000Source | -3,085,000Source | -16,362,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,712,413,000Source | 1,195,420,000Source | 765,327,000Source | 705,744,000Source |
| Additional Paid in Capital, Common StockUSD | 4,488,679,000Source | 3,763,614,000Source | 3,145,837,000Source | 2,664,730,000Source |
| Liabilities and EquityUSD | 2,398,344,000Source | 1,660,735,000Source | 1,441,699,000Source | 1,394,474,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 441,228,000Source | 344,045,000Source | 307,274,000Source | 310,499,000Source |
| Operating Lease, Liability, CurrentUSD | 15,581,000Source | 10,168,000Source | 11,621,000Source | 7,639,000Source |
| Accounts Payable, CurrentUSD | 33,156,000Source | 34,922,000Source | 14,998,000Source | 31,148,000Source |
| Operating Lease, Liability, NoncurrentUSD | 118,473,000Source | 96,588,000Source | 67,025,000Source | 76,577,000Source |
| Other Liabilities, NoncurrentUSD | 11,687,000Source | — | — | — |
| Additional Financial Items | ||||
| Deferred Tax Liabilities, NetUSD | 701,000Source | 25,669,000Source | 15,426,000Source | 20,078,000Source |
| Long-term DebtUSD | — | — | 282,945,000Source | 281,653,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -208,160,000Source | -190,426,000Source | -434,801,000Source | -547,799,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 41,764,000Source | 30,968,000Source | 24,097,000Source | 16,702,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 354,404,000Source | 274,428,000Source | 191,808,000Source | 152,384,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -20,752,000Source | 35,876,000Source | 33,904,000Source | 124,081,000Source |
| Increase (Decrease) in InventoriesUSD | 20,871,000Source | 3,985,000Source | 5,353,000Source | 8,257,000Source |
| Increase (Decrease) in Accounts PayableUSD | 753,000Source | 13,210,000Source | -15,458,000Source | 5,462,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 215,301,000Source | 135,664,000Source | -246,955,000Source | -431,501,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 16,021,000Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -132,209,000Source | 137,624,000Source | 168,498,000Source | 330,338,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 106,188,000Source | 66,423,000Source | 39,199,000Source | 47,697,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 47,461,000Source | 30,204,000Source | 254,461,000Source | 482,640,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 1,076,140,000Source | 945,587,000Source | 642,095,000Source | 466,091,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 4,069,000Source | 7,897,000Source | 11,346,000Source | 8,060,000Source |
| Income Taxes Paid, NetUSD | 499,000Source | 1,307,000Source | 295,000Source | 549,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 354,404,000Source | 274,428,000Source | — | — |
| Amortization of Intangible AssetsUSD | 3,900,000Source | — | — | — |
| DepreciationUSD | 36,500,000Source | 27,200,000Source | 22,700,000Source | 16,700,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -17,000Source | -462,000Source | -265,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | -906,000Source |
| GoodwillUSD | 141,070,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | -59,929,000Source | 695,000Source | 271,000Source | 978,000Source |
| Inventory Write-downUSD | — | 454,000Source | 2,175,000Source | 200,000Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | 2,000Source |
| Net Income (Loss) Attributable to ParentUSD | -208,160,000Source | -190,426,000Source | -434,801,000Source | -547,799,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -547,799,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 23,000,000Source | 314,400,000Source | 306,000,000Source | 216,500,000Source |
| Proceeds from Stock Options ExercisedUSD | 22,536,000Source | 12,988,000Source | 3,892,000Source | 6,411,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | 900,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 2,306,113,000Source | 1,696,911,000Source | 1,082,571,000Source | 820,222,000Source |
| Selling, General and Administrative ExpenseUSD | 1,177,261,000Source | 841,314,000Source | 618,307,000Source | 588,591,000Source |
| Operating Income (Loss)USD | -309,911,000Source | -222,294,000Source | -446,245,000Source | -541,040,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -268,089,000Source | -189,731,000Source | -434,530,000Source | -546,821,000Source |
| Income Tax Expense (Benefit)USD | -59,929,000Source | 695,000Source | 271,000Source | 978,000Source |
| Net Income (Loss) Attributable to ParentUSD | -208,160,000Source | -190,426,000Source | -434,801,000Source | -547,799,000Source |
| Earnings Per Share, BasicUSD per share | -1.52Source | -1.53Source | -3.78Source | -5.57Source |
| Earnings Per Share, DilutedUSD per share | -1.52Source | -1.53Source | -3.78Source | -5.57Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 136,721,000Source | 124,718,000Source | 114,997,000Source | 98,408,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 136,721,000Source | 124,718,000Source | 114,997,000Source | 98,408,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 3,900,000Source | — | — | — |
| Costs and ExpensesUSD | 2,616,024,000Source | 1,919,205,000Source | 1,528,816,000Source | 1,361,262,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -17,000Source | -462,000Source | -265,000Source | — |
| Gain (Loss) on InvestmentsUSD | — | — | — | -906,000Source |
| Interest ExpenseUSD | 4,069,000Source | 10,685,000Source | 12,638,000Source | 9,319,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | 45,891,000Source | 43,248,000Source | 24,353,000Source | 3,538,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | -547,799,000Source |
| Realized Investment Gains (Losses)USD | — | — | — | 900,000Source |
| Research and Development ExpenseUSD | 624,110,000Source | 404,138,000Source | 320,678,000Source | 316,415,000Source |
Filing attachments
ntra-20260630xex991.htm · 8-K · 2026-08-06
EX-99.1 2 ntra-20260630xex991.htm EX-99.1 Document Exhibit 99.1 Natera Reports Second Quarter 2026 Financial Results AUSTIN, Texas, August 6, 2026 /BUSINESS WIRE/ - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2026. Recent Financial Highlights • Generated total revenues of $752.8 million in the second quarter of 2026, compared to $546.6 million in the second quarter of 2025, …
Read attachment ↗ntra-20260630xex992.htm · 8-K · 2026-08-06
EX-99.2 3 ntra-20260630xex992.htm EX-99.2 ntra-20260630xex992 Natera, Inc. Q2’2026 Earnings Presentation August 6, 2026 2 Not for reproduction or further distribution. This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our re…
Read attachment ↗ntra-20260331xex991.htm · 8-K · 2026-05-07
EX-99.1 2 ntra-20260331xex991.htm EX-99.1 Document Exhibit 99.1 Natera Reports First Quarter 2026 Financial Results AUSTIN, Texas, May 7, 2026 /BUSINESS WIRE/ - Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Recent Financial Highlights • Generated total revenues of $696.6 million in the first quarter of 2026, compared to $501.8 million in the first quarter of 2025, an inc…
Read attachment ↗ntra-20260331xex992.htm · 8-K · 2026-05-07
EX-99.2 3 ntra-20260331xex992.htm EX-99.2 ntra-20260331xex992 Natera, Inc. Q1’2026 Earnings Presentation May 7, 2026 2 Not for reproduction or further distribution. This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our reimb…
Read attachment ↗